The influence of clofibrate on lipid and protein components of very low density lipoproteins in type IV hyperlipoproteinaemia.
After 30 days of clofibrate administration to 11 patients with type IV hyperlipoproteinemia, a significant fall was observed in serum triglyceride and cholesterol levels. In the VLDL fraction the concentrations of triglycerides, cholesterol and apo B were significantly decreased. The apo CII/apo CIII ratio was raised. Cholesterol concentration changes in LDL and HDL fractions were not significant.
D000328:Adult; D000368:Aged; D001798:Blood Proteins / Q000032:analysis; D002784:Cholesterol / Q000097:blood; D002994:Clofibrate / Q000494:pharmacology* / Q000627:therapeutic use; D005260:Female; D006801:Humans; D006953:Hyperlipoproteinemia Type IV / Q000188:drug therapy / Q000378:metabolism*; D008079:Lipoproteins, VLDL / Q000097:blood*; D008297:Male; D008875:Middle Aged; D014280:Triglycerides / Q000097:blood
D001798:Blood Proteins; D008079:Lipoproteins, VLDL; D014280:Triglycerides; D002784:Cholesterol; D002994:Clofibrate